Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

Breast Cancer Research and Treatment
H WildiersR Paridaens

Abstract

The aim of this study is to test the hypothesis that antiangiogenic treatment with sunitinib consolidation can prolong remissions induced by taxane-based chemotherapy in women with metastatic breast cancer. The method involves a two-arm open-label (2:1 randomization) multicenter, randomized phase II trial evaluating the efficacy of sunitinib (arm A) versus no therapy (arm B) in patients with HER-2-negative metastatic breast cancer who achieved an objective response to taxane-based chemotherapy. The results of this study indicates that the primary endpoint of progression-free survival (PFS) > or =5 months was achieved in 10 of 36 patients (28%) in arm A and 4 of 19 patients (21%) in arm B. The median PFS was 2.8 and 3.1 months, respectively. A protocol amendment to the sunitinib dosing schedule was made because 53% (17/32) of patients treated at a starting dose of 50 mg (4 weeks on/2 weeks off) required dose reduction. Changing the starting dose to sunitinib 37.5 mg continuously resulted in dose reductions in 44% (7/16) of patients. Grades III-IV toxicity occurred in 69% of patients in arm A (fatigue 31%, musculoskeletal pain 11%, neutropenia and thrombopenia 8%) and 11% in arm B. The proof-of-principle study does not confirm th...Continue Reading

References

Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanJ Crown
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M RavdinR E Bellet
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G FountzilasD Skarlos
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V ValeroH A Burris
Apr 18, 2001·Controlled Clinical Trials·D J SargentR M Goldberg
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeWilliam C Wood
Jun 12, 2003·British Journal of Cancer·H WildiersA T van Oosterom
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandra GennariPier Franco Conte
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinKathy D Miller
Mar 14, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S GeorgeG D Demetri
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonas BerghCarla Giorgetti
Jul 17, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P CrownGilles Romieu

❮ Previous
Next ❯

Citations

Jan 30, 2013·Breast Cancer Research and Treatment·Soley Bayraktar, Stefan Glück
Apr 21, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma
Apr 26, 2012·The Oncologist·Sandro BarniFausto Petrelli
Jan 30, 2014·Japanese Journal of Clinical Oncology·Elham Fakhrejahani, Masakazu Toi
Jan 20, 2015·Expert Review of Clinical Pharmacology·Claudia BozzaGiuseppe Aprile
Feb 22, 2012·Expert Opinion on Investigational Drugs·Marco PetrilloGabriella Ferrandina
Nov 30, 2011·Expert Opinion on Emerging Drugs·Cagatay ArslanOmer Dizdar
Mar 1, 2012·Cancer Treatment Reviews·John R MackeyKathleen I Pritchard
Aug 30, 2011·Cancer Treatment Reviews·Javier Cortes, Henri Roché
Nov 10, 2015·Journal of the National Cancer Institute·Benjamin CarlisleJonathan Kimmelman
Feb 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabio A B SchutzToni K Choueiri
Jul 13, 2012·The Cochrane Database of Systematic Reviews·Anna Dorothea WagnerSusanne Unverzagt
Sep 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K GelmonS Verma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.